Pak Fah Yeow International Ltd
Pak Fah Yeow International Ltd operates in the pharmaceuticals industry, focusing on the development and distribution of healthcare products.
Business. Pak Fah Yeow International Ltd (0239.HK) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Pharmaceuticals & Medical Research sector. Its business model centers on product sales within the broader healthcare industry.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Pak Fah Yeow International Ltd (0239.HK) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Pharmaceuticals & Medical Research sector. Its business model centers on product sales within the broader healthcare industry.
Pak Fah Yeow International Ltd has a market capitalization of 757,285,200 HKD, with a market price of 2.43 HKD per share. The company's capital structure is characterized by a lack of dilution risk, as shares outstanding remain unchanged between basic and diluted counts at 311,640,000. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics indicate a challenging financial position, with the company reporting a negative EPS of -0.06 HKD in the latest period. This suggests that the company is currently unprofitable and may be struggling to generate returns for shareholders. The revenue of 113,802,000 HKD reflects the company's scale of operations, but without comparative industry metrics, it is difficult to assess its relative performance.
The company's geographic and segment exposure is not disclosed in the available data, making it difficult to assess revenue concentration or diversification. This lack of transparency could pose a risk to investors seeking to understand the company's exposure to regional or product-specific downturns.
Looking ahead, the company's growth trajectory is unclear. The latest actual revenue of 113,802,000 HKD does not provide a clear indication of future performance, and no forward-looking guidance is available. The absence of analyst estimates or projections further limits the ability to assess the company's potential for growth.
Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The company is also at risk of continued unprofitability, as evidenced by the negative EPS. There is no indication of dilution risk in the near term, as shares outstanding remain unchanged.
Recent events and filings do not provide additional insight into the company's operations or strategic direction. The lack of detailed disclosures in source documents limits the ability to form a comprehensive view of the company's current status and future prospects.
- The company is currently unprofitable, with a negative EPS of -0.06 HKD.
- Market capitalization stands at 757,285,200 HKD, with no dilution risk identified.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- Revenue of 113,802,000 HKD provides limited insight into the company's scale and performance.
- No forward-looking guidance or analyst estimates are available to assess growth potential.
- The company's geographic and segment exposure is not disclosed, limiting understanding of diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue HK$213.9M, −9,7% YoY; Operating income +9,9% YoY.
- ▍Revenue HK$213.9M, −9,7% YoY
- ▍Operating income +9,9% YoY
- ▍Net income +16,2% YoY
- ▍Net margin 42.7%
Revenue HK$236.8M, −8,6% YoY; Operating income −24,0% YoY.
- ▍Revenue HK$236.8M, −8,6% YoY
- ▍Operating income −24,0% YoY
- ▍Net income −25,1% YoY
- ▍Free cash flow −70,5% YoY
- ▍Net margin 33.2%
Revenue HK$259.2M, +76,1% YoY; Operating income +236,9% YoY.
- ▍Revenue HK$259.2M, +76,1% YoY
- ▍Operating income +236,9% YoY
- ▍Net income +250,7% YoY
- ▍Free cash flow +386,2% YoY
- ▍Net margin 40.5%
Revenue HK$147.2M, +5,3% YoY; Operating income −19,1% YoY.
- ▍Revenue HK$147.2M, +5,3% YoY
- ▍Operating income −19,1% YoY
- ▍Net income −21,6% YoY
- ▍Free cash flow −47,1% YoY
- ▍Net margin 20.3%
Revenue HK$139.8M; Operating income HK$47.5M.
- ▍Revenue HK$139.8M
- ▍Operating income HK$47.5M
- ▍Net margin 27.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Pak Fah Yeow International Ltd Market data — financials · 2026-05-26
- Pak Fah Yeow International Ltd Market data — analyst estimates · 2026-05-26